CDC Reports Cases of Multisystem Inflammatory Syndrome in Adults
Small data set indicates that adults with current or previous SARS-CoV-2 can develop hyperinflammatory syndrome.
Miscellaneous Respiratory Disorders
Benralizumab Looks Promising in Nasal Polyps Trial
The 56-week OSTRO trial evaluated the efficacy and safety of benralizumab, an interleukin-5 antagonist, in 413 adult patients with severe nasal polyposis.
Dupixent Prefilled Pen Approval Provides Additional Administration Option
The FDA has approved a prefilled pen formulation of Dupixent (dupilumab; Sanofi and Regeneron), providing another option for administering the treatment.
Brensocatib Receives Breakthrough Tx Status for Non-Cystic Fibrosis Bronchiectasis
The FDA has granted Breakthrough Therapy designation to brensocatib (INS1007; Insmed) for the treatment of adults with non-cystic fibrosis bronchiectasis for reducing exacerbations.
First Study Investigating Antibody Treatment for COVID-19 Begins
The first patients have been dosed in a phase 1 trial evaluating a potential antibody therapy designed to treat coronavirus disease 2019. These patients received treatment at major medical centers in the US, including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles.
ATS Provides Interim Guidance for Management of COVID-19
Hydroxychloroquine, chloroquine suggested for hospitalized patients with COVID-19, severe pneumonia.
Survey: Management of Amikacin Liposome Inhalation Suspension-Associated Respiratory Adverse Events
Findings from patient-directed survey showed that the most commonly reported respiratory adverse events included dysphonia, increased sputum production, increased cough and dyspnea.
Pirfenidone Gets Breakthrough Therapy Status for Unclassifiable Interstitial Lung Disease
The FDA has granted Breakthrough Therapy designation to pirfenidone (Esbriet®; Genentech) for adults with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of fibrosing ILD (“unclassifiable” interstitial lung disease [uILD]).
Nebulized Normal Saline Evaluated for Acute Viral Bronchiolitis
Although no differences were seen in the standardized mean differences for respiratory rate or oxygen saturation when comparing nebulized normal saline with another placebo, a difference in respiratory scores which favored nebulized normal saline by -0.9 points was observed 60 minutes posttreatment.
Wearable Device Data May Help Predict Flu-Like Illness Patterns
Fitbit data significantly improved prediction of influenza-like illness in top five states with most users
